Cyclacel Pharmaceuticals to Participate in Major Investment Conference
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP) is gearing up to present its cutting-edge cancer therapies at the upcoming H.C. Wainwright 26th Annual Global Investment Conference. This event serves as an excellent opportunity for investors to connect with biopharmaceutical companies that are at the forefront of medical innovation.
Event Details
Taking place from September 9-11 in New York, the conference will also offer virtual participation options. Cyclacel’s President & CEO, Spiro Rombotis, will conduct a presentation outlining the company’s strategic plans and progress in oncology, giving potential investors insight into the company’s future trajectory.
Logistics of the Event
With over 550 company presentations available either live or on-demand, the conference aims to cater to a wide range of institutional investors. Those interested in learning more can find access to the presentation through the investor relations section on Cyclacel’s website.
About Cyclacel Pharmaceuticals
Cyclacel Pharmaceuticals is dedicated to creating innovative therapies aimed at fighting cancer through a comprehensive understanding of cell cycle regulation and mitotic processes. Among their key products under development are fadraciclib, a CDK2/9 inhibitor, and plogosertib, a PLK1 inhibitor, both of which are being assessed for their effectiveness against solid tumors and various blood cancers.
Strategic Focus and Development Pipeline
The company is focused on building a diverse portfolio by developing unique drug candidates that meet critical needs in oncology and hematology. This commitment to innovation and effectiveness is anticipated to drive growth and deliver value to both shareholders and patients.
Contact Information for the Company
For any inquiries, you can reach Cyclacel Pharmaceuticals through Paul McBarron at (908) 517-7330 or via email at IR@cyclacel.com.
Frequently Asked Questions
What is the H.C. Wainwright Global Investment Conference?
The H.C. Wainwright conference is an annual gathering where various companies showcase their investment opportunities to institutional investors.
Who will represent Cyclacel at the conference?
Spiro Rombotis, the President & CEO of Cyclacel Pharmaceuticals, will be the one presenting.
What are the main focus areas for Cyclacel?
Cyclacel is concentrated on developing innovative cancer therapies informed by insights from cellular and cancer biology.
How can investors view Cyclacel’s presentation?
Investors will have the option to access the presentation either live or on-demand, with further details available on Cyclacel's website.
What are the key products in Cyclacel's development pipeline?
The primary products include fadraciclib and plogosertib, which are being developed for the treatment of various cancers.
